Copper Kills Cancer Cells. Then the Immune System Finishes the Job.

Cancer immunotherapy has transformed oncology over the past decade, but a substantial share of patients either never respond or eventually stop responding. A new preclinical study from The University of Texas MD Anderson Cancer Center, published in Cell on June 22, 2026, points toward an unexpected ally in that problem: copper. The findings are early and come from animal models, but they describe a two-way reinforcing cycle between copper-driven cell death and immune activation that researchers believe could be harnessed to revive stalled immunotherapy responses.

Cuproptosis Triggers an Immune Alarm in Dying Tumor Cells

Cuproptosis is a recently identified form of regulated cell death, distinct from apoptosis or necroptosis, that occurs when copper ions accumulate inside a cell at toxic levels. As the copper builds up, it disrupts mitochondrial respiration and causes proteins involved in the tricarboxylic acid cycle to aggregate abnormally, a process sometimes described as proteotoxic stress. The result is a form of cell death that operates through nontraditional pathways compared to the more familiar programmed death mechanisms.

What the MD Anderson team found, led by Boyi Gan, Ph.D., professor of Experimental Radiation Oncology, is that cancer cells dying via cuproptosis do not simply collapse in silence. They release damage-associated molecular patterns, known as DAMPs, which act as immunogenic signals. These signals activate dendritic cells, which in turn prime CD8-positive T cells, the cytotoxic immune cells responsible for hunting and killing cancer. This classifies cuproptotic tumor cell death as a form of immunogenic cell death, a category of dying that the immune system interprets as a call to arms rather than a routine housekeeping event.

The Feedback Loop: CD8 T Cells Make Tumors More Vulnerable to Copper

The more striking part of the finding is that the relationship runs in both directions. Activated CD8-positive T cells do not just respond to cuproptosis: they also enhance cancer cell susceptibility to it. This reinforcing interaction between cuproptosis and immune cells means that the more immune cells are activated, the more vulnerable remaining tumor cells become to copper-induced death, and the more cancer cells undergo cuproptosis, the stronger the immune signal grows.

In preclinical animal models, combining a cuproptosis-inducing treatment with anti-PD-L1 immunotherapy significantly slowed tumor growth. Critically, the combination worked even in models that were resistant to anti-PD-L1 therapy alone. This suggests the copper-driven cell death is not simply additive with immunotherapy but may actively reprogram the tumor microenvironment in a way that restores immune sensitivity. The potential clinical relevance is considerable given that immunotherapy resistance represents one of the field's most pressing unsolved problems.

FDX1 as a Potential Biomarker for Patient Selection

Not all tumors are equally sensitive to cuproptosis. The gene FDX1, which encodes ferredoxin 1, a mitochondrial reductase involved in intracellular copper handling and redox balance, appears to be a key determinant of susceptibility. In the study, higher FDX1 expression was linked to better treatment responses. This raises the possibility that FDX1 could serve as a patient-selection biomarker, helping clinicians identify which cancers are most likely to respond to a cuproptosis-based combination strategy before treatment begins.

The broader landscape of copper metabolism in cancer has attracted growing interest precisely because some tumor types appear to depend heavily on copper for proliferation and metabolic activity, potentially making them especially vulnerable to copper-targeting approaches. The MD Anderson findings fit into this larger picture by showing that the immune consequences of copper-induced death, not just the cell-killing itself, may be where the real therapeutic leverage lies.

Limitations: Preclinical Results Require Clinical Validation

It is important to be precise about what this study does and does not show. All experiments were conducted in animal models. The leap from preclinical success to human efficacy is uncertain, and the history of cancer research is full of treatments that performed well in mice but failed in clinical trials. Ongoing work will need to refine the molecular markers that predict response, determine appropriate dosing regimens, and evaluate both long-term efficacy and safety across diverse cancer types and patient populations.

Gan acknowledged this directly, noting that the cuproptosis-inducing agents used in the study already carry clinical experience and favorable safety profiles, which he described as "a practical path toward developing new combination treatments for patients whose cancers no longer respond to immunotherapy." That existing clinical familiarity does lower some of the translational risk compared to entirely novel compounds, but it does not replace the need for rigorous human trials.

What Comes Next in Copper-Based Cancer Research

The scientific community's understanding of cuproptosis is still developing rapidly; the mechanism was only formally described within the last few years, and its interactions with the immune system were not well characterized before work like this. Research groups beyond MD Anderson are also pursuing copper-based strategies: a clinical trial at Dartmouth Cancer Center, for example, is now enrolling patients with triple-negative breast cancer to test copper depletion as a way to prevent tumor spread, illustrating how varied the therapeutic angles on copper biology have become.

For the MD Anderson approach, the immediate priorities are translating the biomarker findings around FDX1 into a clinical selection framework and designing early-phase trials that pair cuproptosis-inducing agents with checkpoint inhibitors in patients whose tumors have stopped responding to immunotherapy alone. If the preclinical signal holds, the combination could represent a meaningfully different strategy for a patient population that currently has few good options.

Evidence rating

INVESTIGATIONAL — 65/100

Preclinical study using animal tumor models only; no human participants. Demonstrates a mechanistic causal chain between cuproptosis signaling, CD8+ T cell activation, and anti-PD-L1 synergy, but results cannot be extrapolated to clinical outcomes without human trials. Findings have not yet been independently replicated.

References

1. Copper-induced cell death stimulates antitumor immune cell responses. https://www.news-medical.net/news/20260622/Copper-induced-cell-death-stimulates-antitumor-immune-cell-responses.aspx
2. Chengliang Pan, Zhilin Ji, Qingxuan Wang, et al. (2024). Cuproptosis: Mechanisms, biological significance, and advances in disease treatment—A systematic review. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70039
3. Xinjia He, Yingke Wen, Yanjie Fang, Mengjie Li, Bing Shan (2024). Charge Photoaccumulation in Covalent Polymer Networks for Boosting Photocatalytic Nitrate Reduction to Ammonia. Advanced Science. https://doi.org/10.1002/advs.202401878
4. Ruimin Kong, Guojuan Sun (2023). Targeting copper metabolism: a promising strategy for cancer treatment. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2023.1203447
5. Chloe Springer, Danish Humayun, Rachid Skouta (2024). Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy. Cancers. https://doi.org/10.3390/cancers16030647
6. Copper Trial for Triple-Negative Breast Cancer Officially Opens to Patients | News & Stories. cancer.dartmouth.edu. https://cancer.dartmouth.edu/news/2024/12/10/copper-trial-triple-negative-breast-cancer-officially-opens-patients